New England Peptide of Gardner and the Atlantic Cancer Research Institute of New Brunswick, Canada, have formed a partnership to develop cancer-related peptide reagents.
Peptides that bind strongly to cancer-related proteins could have multiple research applications for a wide range of cell types and human tissues, the nonprofit ACRI said.
New England Peptide, which produces custom peptides used in scientific research, said the reagents developed by the partnership have potential to be used in cancer diagnostics and treatments.
“The materials are still in the testing phase, but we anticipate that our research partnership will culminate in a series of commercial products,” NEP said.
Financial terms of the partnership were not disclosed.
